Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial

Purpose: Prospectively scored radiation pneumonitis (RP) observed in a national, randomized phase II dose-escalation trial for patients with locally advanced non-small cell lung cancer (NSCLC) was investigated. Methods: Patients with stage IIB-IIIB histologically proven NSCLC were treated with conco...

Full description

Bibliographic Details
Main Authors: Christina M. Lutz, Marianne M. Knap, Lone Hoffmann, Ditte S. Møller, Olfred Hansen, Carsten Brink, Tine Schytte, Christa H. Nyhus, Tine McCulloch, Svetlana Borissova, Markus Alber, Azza A. Khalil
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:Clinical and Translational Radiation Oncology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630820301002
id doaj-c71c88fe9d9047ac84a6c37ef1fc226b
record_format Article
spelling doaj-c71c88fe9d9047ac84a6c37ef1fc226b2021-06-02T21:02:03ZengElsevierClinical and Translational Radiation Oncology2405-63082021-03-0127814Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trialChristina M. Lutz0Marianne M. Knap1Lone Hoffmann2Ditte S. Møller3Olfred Hansen4Carsten Brink5Tine Schytte6Christa H. Nyhus7Tine McCulloch8Svetlana Borissova9Markus Alber10Azza A. Khalil11Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Corresponding author at: Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark.Department of Oncology, Aarhus University Hospital, Aarhus, DenmarkDepartment of Oncology, Aarhus University Hospital, Aarhus, DenmarkDepartment of Oncology, Aarhus University Hospital, Aarhus, DenmarkDepartment of Oncology, Odense University Hospital, Odense, DenmarkDepartment of Oncology, Odense University Hospital, Odense, DenmarkDepartment of Oncology, Odense University Hospital, Odense, DenmarkDepartment of Oncology, Vejle Hospital, Vejle, DenmarkDepartment of Oncology, Aalborg Hospital, Aalborg, DenmarkDepartment of Oncology, Herlev Hospital, Herlev, DenmarkHeidelberg Institute for Radiation Oncology, Heidelberg University Hospital, Heidelberg, GermanyDepartment of Oncology, Aarhus University Hospital, Aarhus, DenmarkPurpose: Prospectively scored radiation pneumonitis (RP) observed in a national, randomized phase II dose-escalation trial for patients with locally advanced non-small cell lung cancer (NSCLC) was investigated. Methods: Patients with stage IIB-IIIB histologically proven NSCLC were treated with concomitant chemo-radiotherapy (oral Vinorelbine 3times/week) at 60 Gy/30fx (A–59pts) and 66 Gy/33fx (B–58pts) from 2009 to 2013 at five Danish RT centers. Grade 2 RP (CTCAEv3.0) was investigated with univariate analysis for association with clinical and dosimetric parameters, including dyspnea and cough at baseline and during RT. Multivariable logistic regression and Cox regression with regularization were used to find a multivariable model for RP ≥ G2. Results: Despite a tendency of higher mean lung dose in the high-dose arm (median[range] A = 14.9 Gy[5.8,23.1], B = 17.5 Gy[8.6,24.8], p = 0.075), pulmonary toxicities were not significantly different (RP ≥ G2 41%(A) and 52%(B), p = 0.231). A Kaplan Meier analysis of the time to RP ≥ G2 between the two arms did not reach statistical significance (p = 0.180). Statistically significant risk factors for RP ≥ G2 were GTV size (OR = 2.091/100 cm3, p = 0.002), infection at baseline or during RT (OR = 8.087, p = 0.026), dyspnea at baseline (OR = 2.184, p = 0.044) and increase of cough during RT (OR = 2.787, p = 0.008). In the multivariable logistic regression and the Cox regression analysis, the deviances of the most predictive models were within one standard deviation of the null model. Conclusion: No statistical difference between the high- and low dose arm was found in the risk of developing RP. The univariate analysis identified target volume, infection, dyspnea at baseline, and increase of cough during RT as risk factors for RP. The number of patients was too small to establish a statistically sound multivariable model.http://www.sciencedirect.com/science/article/pii/S2405630820301002ProspectiveRadiation pneumonitisLocally-advanced non-small cell lung cancer
collection DOAJ
language English
format Article
sources DOAJ
author Christina M. Lutz
Marianne M. Knap
Lone Hoffmann
Ditte S. Møller
Olfred Hansen
Carsten Brink
Tine Schytte
Christa H. Nyhus
Tine McCulloch
Svetlana Borissova
Markus Alber
Azza A. Khalil
spellingShingle Christina M. Lutz
Marianne M. Knap
Lone Hoffmann
Ditte S. Møller
Olfred Hansen
Carsten Brink
Tine Schytte
Christa H. Nyhus
Tine McCulloch
Svetlana Borissova
Markus Alber
Azza A. Khalil
Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial
Clinical and Translational Radiation Oncology
Prospective
Radiation pneumonitis
Locally-advanced non-small cell lung cancer
author_facet Christina M. Lutz
Marianne M. Knap
Lone Hoffmann
Ditte S. Møller
Olfred Hansen
Carsten Brink
Tine Schytte
Christa H. Nyhus
Tine McCulloch
Svetlana Borissova
Markus Alber
Azza A. Khalil
author_sort Christina M. Lutz
title Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial
title_short Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial
title_full Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial
title_fullStr Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial
title_full_unstemmed Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial
title_sort prospectively scored pulmonary toxicities in non-small cell lung cancer: results from a randomized phase ii dose escalation trial
publisher Elsevier
series Clinical and Translational Radiation Oncology
issn 2405-6308
publishDate 2021-03-01
description Purpose: Prospectively scored radiation pneumonitis (RP) observed in a national, randomized phase II dose-escalation trial for patients with locally advanced non-small cell lung cancer (NSCLC) was investigated. Methods: Patients with stage IIB-IIIB histologically proven NSCLC were treated with concomitant chemo-radiotherapy (oral Vinorelbine 3times/week) at 60 Gy/30fx (A–59pts) and 66 Gy/33fx (B–58pts) from 2009 to 2013 at five Danish RT centers. Grade 2 RP (CTCAEv3.0) was investigated with univariate analysis for association with clinical and dosimetric parameters, including dyspnea and cough at baseline and during RT. Multivariable logistic regression and Cox regression with regularization were used to find a multivariable model for RP ≥ G2. Results: Despite a tendency of higher mean lung dose in the high-dose arm (median[range] A = 14.9 Gy[5.8,23.1], B = 17.5 Gy[8.6,24.8], p = 0.075), pulmonary toxicities were not significantly different (RP ≥ G2 41%(A) and 52%(B), p = 0.231). A Kaplan Meier analysis of the time to RP ≥ G2 between the two arms did not reach statistical significance (p = 0.180). Statistically significant risk factors for RP ≥ G2 were GTV size (OR = 2.091/100 cm3, p = 0.002), infection at baseline or during RT (OR = 8.087, p = 0.026), dyspnea at baseline (OR = 2.184, p = 0.044) and increase of cough during RT (OR = 2.787, p = 0.008). In the multivariable logistic regression and the Cox regression analysis, the deviances of the most predictive models were within one standard deviation of the null model. Conclusion: No statistical difference between the high- and low dose arm was found in the risk of developing RP. The univariate analysis identified target volume, infection, dyspnea at baseline, and increase of cough during RT as risk factors for RP. The number of patients was too small to establish a statistically sound multivariable model.
topic Prospective
Radiation pneumonitis
Locally-advanced non-small cell lung cancer
url http://www.sciencedirect.com/science/article/pii/S2405630820301002
work_keys_str_mv AT christinamlutz prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial
AT mariannemknap prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial
AT lonehoffmann prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial
AT dittesmøller prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial
AT olfredhansen prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial
AT carstenbrink prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial
AT tineschytte prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial
AT christahnyhus prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial
AT tinemcculloch prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial
AT svetlanaborissova prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial
AT markusalber prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial
AT azzaakhalil prospectivelyscoredpulmonarytoxicitiesinnonsmallcelllungcancerresultsfromarandomizedphaseiidoseescalationtrial
_version_ 1721400980972503040